Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Tilray BrandsTLRY -2.76%51 Earnings Yield (Joel Greenblatt) % is -144.93% as of Feb. 2026. GuruFocus rates TLRY with a GF Score™ of 51/100 and a GF Value™ of $12.50 (Possible Value Trap). The stock has 4 warning signs investors should review. Among 1,011 Drug Manufacturers companies, Tilray Brands ranks worse than 98.81% on this metric.
Tilray Brands's Enterprise Value for the quarter that ended in Feb. 2026 was $980.1 Mil.
Tilray Brands's EBIT for the trailing twelve months (TTM) ended in Feb. 2026 was $-1,424.7 Mil. Tilray Brands's Earnings Yield (Joel Greenblatt) for the quarter that ended in Feb. 2026 was -144.93%.
The historical rank and industry rank for Tilray Brands's Earnings Yield (Joel Greenblatt) % or its related term are showing as below:
TLRY'
s Earnings Yield (Joel Greenblatt) % Range Over the Past 10 Years
Min: -561.21 Med: -6.67 Max: 6.73
Current: -263.16
During the past 13 years, the highest Earnings Yield (Joel Greenblatt) of Tilray Brands was 6.73%. The lowest was -561.21%. And the median was -6.67%.
TLRY's Earnings Yield (Joel Greenblatt) % is ranked worse than 98.81% of 1011
companies
in the Drug Manufacturers industry
Industry Median: 3.31
vs TLRY: -263.16
Joel Greenblatt's definition of earnings yield has the same problems the regular earnings yield does. It does not consider the growth of the company. It only looks at one-year's business operation. For cyclical companies, the earnings yield is usually highest at the peak of the business cycle. But these earnings are rarely sustainable.
A better indicator of the attractiveness of an investment which takes growth into account is the Forward Rate of Return (Yacktman) %. Tilray Brands's Forward Rate of Return (Yacktman) % for the quarter that ended in Feb. 2026 was 0.00%. The Forward Rate of Return uses the normalized Free Cash Flow of the past five years, and considers growth. The forward rate of return can be thought of as the return that investors buying the stock today can expect from it in the future.
Joel Greenblatt defines the earnings yield using the above equation because it more accurately reflects the company's profitability relative to its stock price. Items like interest payment and tax etc. are not directly related to the company's operational profitability.
Enterprise Value instead of market cap (share price) is used in the calculation because it is the real price stock and bond investors together pay for the company.
Be Aware
Joel Greenblatt's definition of earnings yield has the same problems the regular earnings yield does. It does not consider the growth of the company. It only looks at one-year's business operation. For cyclical companies, the earnings yield is usually highest at the peak of the business cycle. But these earnings are rarely sustainable.
Tilray Brands Earnings Yield (Joel Greenblatt) % Related Terms
Tilray Brands Earnings Yield (Joel Greenblatt) % Historical Data
* Premium members only.
The historical data trend for Tilray Brands's Earnings Yield (Joel Greenblatt) % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Tilray Brands's Earnings Yield (Joel Greenblatt) %, along with its competitors' market caps and Earnings Yield (Joel Greenblatt) % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Tilray Brands Earnings Yield (Joel Greenblatt) % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Tilray Brands's Earnings Yield (Joel Greenblatt) % distribution charts can be found below:
* The bar in red indicates where Tilray Brands's Earnings Yield (Joel Greenblatt) % falls into.
In his book, The Little That Beat the Market, hedge fund manager Joel Greenblatt defines Earnings Yield as operating income divided by enterprise value.
Tilray Brandss Earnings Yield (Joel Greenblatt) for the fiscal year that ended in May. 2025 is calculated as
Tilray Brands's EBIT for the trailing twelve months (TTM) ended in Feb. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-1,424.7 Mil.
What does a Earnings Yield (Joel Greenblatt) % of -144.93% mean?
Tilray Brands (TLRY) has a Earnings Yield (Joel Greenblatt) % of -144.93% as of Feb. 2026. Joel Greenblatt's earnings yield equals the ratio of earnings before interest and taxes to enterprise value. View historical data on Tilray Brands and its competitors. According to the industry distribution chart, Tilray Brands ranks #999 out of 1011 companies in the Drug Manufacturers industry, placing it in the top 98.8%.
Is Tilray Brands' Earnings Yield (Joel Greenblatt) % too high?
Tilray Brands' current Earnings Yield (Joel Greenblatt) % is -144.93%. Based on the distribution chart, Tilray Brands ranks #999 out of 1011 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Tilray Brands has a GF Score™ of 51/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Tilray Brands' Earnings Yield (Joel Greenblatt) % compare to AQST and EOLS?
According to the Drug Manufacturers industry distribution chart, Tilray Brands ranks #999 out of 1011 companies for Earnings Yield (Joel Greenblatt) %. This places Tilray Brands in the lower half of its industry. The industry median Earnings Yield (Joel Greenblatt) % is 3.31. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Earnings Yield (Joel Greenblatt) % for a Drug Manufacturers company?
The median Earnings Yield (Joel Greenblatt) % among Drug Manufacturers companies is 3.31, based on 1,011 companies in the industry. Companies in the top quartile (top 25%) have a Earnings Yield (Joel Greenblatt) % significantly above this median, while those in the bottom quartile fall well below. However, Earnings Yield (Joel Greenblatt) % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Earnings Yield (Joel Greenblatt) % mean?
A high Earnings Yield (Joel Greenblatt) % can signal that a stock is expensive relative to its fundamentals. Joel Greenblatt's earnings yield equals the ratio of earnings before interest and taxes to enterprise value. View historical data on Tilray Brands and its competitors. For the Drug Manufacturers industry, the median Earnings Yield (Joel Greenblatt) % is 3.31 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Tilray Brands's current Earnings Yield (Joel Greenblatt) % is -144.93%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Tilray Brands stock overvalued right now?
Based on GuruFocus' analysis, Tilray Brands (TLRY) is currently considered Possible Value Trap. The stock's GF Value™ is $12.50, compared to a current price of $3.88 — trading 69% below its estimated fair value. The current Earnings Yield (Joel Greenblatt) % is -144.93%. Tilray Brands' overall GF Score™ is 51/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Earnings Yield (Joel Greenblatt) % calculated?
Earnings Yield (Joel Greenblatt) % is calculated from a company's financial statements. For Tilray Brands (TLRY), the current Earnings Yield (Joel Greenblatt) % is -144.93% as of Feb. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Tilray Brands (TLRY) Overvalued in 2026?
Based on GuruFocus' analysis, Tilray Brands stock appears to be undervalued.
The current stock price of $3.88 is trading 69% below its estimated GF Value™ of $12.50.
GuruFocus considers Tilray Brands to be Possible Value Trap.
Key valuation signals for TLRY:
Earnings Yield (Joel Greenblatt) %: -144.93%
GF Value™: $12.50 vs. price of $3.88 (69% below fair value)
No single metric tells the full story. See the TLRY stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Tilray is a Canadian producer that cultivates and sells medical and recreational cannabis. In 2021, legacy Aphria acquired legacy Tilray in a reverse merger and renamed itself Tilray. The bulk of its sales are in Canada and in the international medical cannabis export market. US exposure comes mainly from alcohol.
51GF Score
Get the complete analysis for TLRY
Earnings Yield (Joel Greenblatt) % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TLRY has been successfully added to your 
